Perspective
Volume 15:02, 2025

Journal of Bioengineering & Biomedical Science

ISSN:2155-9538 Open Access

Multiplexed Nanoparticle-based Assays for Infectious Disease Screening

Krysko Turner*

Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan

Introduction

The rapid and accurate detection of infectious diseases remains a critical challenge in global healthcare, particularly in areas where access to advanced diagnostic infrastructure is limited. Early detection of pathogens is essential for effective treatment, controlling outbreaks and reducing the burden on healthcare systems. Traditional diagnostic methods, such as culture-based assays or PCR (Polymerase Chain Reaction), are highly effective but can be time-consuming, expensive and labor-intensive. In recent years, significant strides have been made in developing multiplexed nanoparticle-based assays that promise to revolutionize the way infectious diseases are diagnosed. The use of nanoparticles in diagnostic assays leverages their ability to interact with biomolecules at the nanoscale, facilitating the development of highly sensitive detection systems. Gold nanoparticles, magnetic nanoparticles and quantum dots are among the most commonly used in these assays, each providing distinct advantages in terms of signal generation, ease of functionalization and compatibility with various detection methods. These assays have the potential to provide rapid, point-of-care diagnostic solutions, particularly in resource-limited settings, where timely diagnosis can significantly impact patient outcomes and public health interventions. The integration of these advanced diagnostic technologies into clinical practice could transform how infectious diseases are diagnosed, monitored and managed, leading to better control and more effective treatment strategies [1].

Description

The global healthcare landscape is continually challenged by the need for rapid, accurate and affordable diagnostic tools, particularly in the context of infectious diseases. Early detection is crucial for effective treatment, preventing the spread of pathogens and managing outbreaks. However, traditional diagnostic methods, such as culture-based assays, Polymerase Chain Reaction (PCR) and Enzyme-Linked Immunosorbent Assays (ELISA), while effective, can be time-consuming, expensive and require specialized infrastructure, limiting their use in resource-limited settings. In response to these challenges, multiplexed nanoparticle-based assays have emerged as a promising solution, offering a novel approach for the rapid and simultaneous detection of multiple infectious agents. Nanoparticles, due to their unique physical and chemical properties, are increasingly being used in diagnostic assays to improve the sensitivity and specificity of tests. These small particles, typically ranging in size from 1 to 100 nanometres, can be engineered to interact with biomolecules such as proteins, nucleic acids, or antibodies. When used in diagnostic assays, nanoparticles enhance the detection process, enabling the identification of pathogens at much lower concentrations than traditional methods would allow. Multiplexed nanoparticle-based assays combine this enhanced sensitivity with the ability to simultaneously detect multiple biomarkers or pathogens in a single test, which is a significant advantage over conventional single-pathogen detection methods [2].

The advantages of multiplexed nanoparticle-based assays lie in their ability to detect a wide variety of infectious agents in one go. Several types of nanoparticles are commonly used in these assays, including Gold Nanoparticles (AuNPs), Magnetic Nanoparticles (MNPs) and Quantum Dots (QDs), each offering distinct advantages. Gold nanoparticles, for instance, are widely used due to their easy synthesis, excellent biocompatibility and ability to undergo surface modifications. This allows for easy conjugation with various biomolecules, such as antibodies or DNA probes, which are used to target specific pathogens or biomarkers. Gold nanoparticles also exhibit unique optical properties, such as surface plasmon resonance (SPR), which enables visual detection without the need for sophisticated instrumentation. Magnetic nanoparticles, on the other hand, are often used for their ease of separation and high sensitivity in the detection of target pathogens. When functionalized with ligands that bind to specific biomolecules, MNPs can be collected using a magnetic field, making it easier to isolate and concentrate the analytes from a complex sample. The magnetic properties of these nanoparticles also facilitate the detection of pathogens using methods like Magnetic Resonance Imaging (MRI) or magnetic assays [3].

Quantum dots are semiconductor nanoparticles that possess unique fluorescent properties, making them ideal for highly sensitive, multiplexed detection. When quantum dots are exposed to light, they emit specific wavelengths of fluorescence depending on their size. By conjugating quantum dots with specific probes that bind to pathogens, researchers can detect multiple pathogens at once, each emitting a distinct fluorescence signal. This allows for a wide range of simultaneous pathogen detection in a single assay, making quantum dots a powerful tool for multiplexing in infectious disease diagnostics. The combination of multiplexing capabilities and the unique properties of nanoparticles enables these assays to provide faster and more accurate diagnostics, especially in point-of-care settings. In addition to their speed and sensitivity, multiplexed nanoparticle-based assays also provide a high degree of flexibility. These assays can be tailored to detect a wide range of infectious agents, including bacteria, viruses, fungi and parasites. This broad diagnostic capacity is particularly useful in the context of emerging infectious diseases, where the pathogens involved may not always be known or predictable. The ability to detect multiple agents at once can be a crucial tool for monitoring outbreaks, providing early warning signals for public health interventions [4].

Multiplexed nanoparticle-based assays also have the potential to reduce the overall cost of diagnostic testing. Traditional diagnostic techniques often require multiple tests to identify different pathogens, each involving separate reagents, equipment and time. In contrast, multiplexed assays consolidate the detection process, requiring only a single test for multiple pathogens. This not only reduces the cost of reagents and equipment but also streamlines laboratory workflow, freeing up valuable resources and time for other tasks. Despite their considerable promise, there are several challenges to the widespread adoption of multiplexed nanoparticle-based assays. The development of standardized,

***Address for Correspondence:** Krysko Turner, Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan, E-mail: turner.krysko@cgu.tw*

Received: 01 April, 2025, Manuscript No. jbbs-25-165627; **Editor Assigned:** 03 April, 2025, PreQC No. P-165627; **Reviewed:** 15 April, 2025, QC No. Q-165627; **Revised:** 22 April, 2025, Manuscript No. R-165627; **Published:** 29 April, 2025, DOI: 10.37421/2155-9538.2025.15.472

user-friendly platforms is essential for ensuring that these assays can be reliably used in real-world healthcare settings. Another challenge is the need for effective detection systems that can handle the large amount of data generated by multiplexed assays. While nanoparticles offer highly sensitive and specific detection, their application in multiplexed formats often requires sophisticated optical, electrochemical, or magnetic detection systems. Regulatory approval and clinical validation are additional hurdles that must be overcome before these assays can be widely implemented in clinical practice. While the concept of nanoparticle-based diagnostics is promising, these technologies must undergo rigorous testing to ensure their accuracy, safety and performance in real-world scenarios. Clinical trials and regulatory oversight are essential steps in bringing these innovative assays to market, ensuring that they meet the necessary standards for patient care [5].

Conclusion

In conclusion, multiplexed nanoparticle-based assays represent a promising frontier in the rapid, sensitive and simultaneous detection of infectious diseases. These assays offer several advantages over traditional diagnostic methods, including increased speed, sensitivity and the ability to detect multiple pathogens in a single test. As the technology matures and overcomes the existing challenges of standardization, scalability and regulatory approval, multiplexed nanoparticle-based assays are poised to play a transformative role in infectious disease diagnosis, improving patient outcomes and enabling more effective public health surveillance.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Zhang, Xiao-Xi, Jing-Shu Liu, Le-Fei Han and Shang Xia, et al. "Towards a global One Health index: A potential assessment tool for One Health performance." *Infect Dis Poverty* 11 (2022): 12-26.

2. Rudolf, Frauke, Mads Damkjaer, Suzanne Lunding and Kenn Dornonville de la Cour, et al. "Influence of referral pathway on Ebola virus disease case-fatality rate and effect of survival selection bias." *Emerg Infect* Dis 23 (2017): 597.

3. Kass, Daniel J., Mehdi Nouraie, Marilyn K. Glassberg and Nitya Ramreddy, et al. "Comparative profiling of serum protein biomarkers in rheumatoid arthritis–associated interstitial lung disease and idiopathic pulmonary fibrosis." *Arthritis Rheumatol* 72 (2020): 409-419.

4. Asdaq, Syed Mohammed Basheeruddin, Abu Md Ashif Ikbal, Ram Kumar Sahu and Bedanta Bhattacharjee, et al. "Nanotechnology integration for SARS-CoV-2 diagnosis and treatment: an approach to preventing pandemic." *Nanomaterials* 11 (2021): 1841.

5. Engelmann, Ilka, Clémence Mordacq, Philippe Gosset and Isabelle Tillie-Leblond, et al. "Rhinovirus and asthma: Reinfection, not persistence." *Am J Respir Crit Care Med* 188 (2013): 1165-1167.

How to cite this article: Turner, Krysko. "Multiplexed Nanoparticle-based Assays for Infectious Disease Screening." *J Bioengineer & Biomedical Sci* 15 (2025): 472.